journal
MENU ▼
Read by QxMD icon Read
search

Human Psychopharmacology

journal
https://www.readbyqxmd.com/read/28517911/is-there-a-potential-of-misuse-for-magnolia-officinalis-compounds-metabolites
#1
Fabrizio Schifano, Valentina Guarino, Duccio G Papanti, Jacopo Baccarin, Laura Orsolini, John M Corkery
OBJECTIVE: Magnolia bark contains magnolol, metabolized to tetrahydromagnolol and honokiol, with both GABA-ergic/cannabimimetic activities, hence of possible attraction to vulnerable individuals/recreational misusers. METHODS: A literature review, assessment of related anecdotal online Magnolia misuse's reports and an overview of Magnolia products' online acquisition possibilities has been here described. RESULTS: No peer-reviewed papers about Magnolia abuse/misuse/dependence/addiction were identified...
May 18, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28517366/genie-in-a-blotter-a-comparative-study-of-lsd-and-lsd-analogues-effects-and-user-profile
#2
Leigh D Coney, Larissa J Maier, Jason A Ferris, Adam R Winstock, Monica J Barratt
OBJECTIVE: This study aimed to describe self-reported patterns of use and effects of lysergic acid diethylamide (LSD) analogues (AL-LAD, 1P-LSD, and ETH-LAD) and the characteristics of those who use them. METHODS: An anonymous self-selected online survey of people who use drugs (Global Drug Survey 2016; N = 96,894), which measured perceived drug effects of LSD and its analogues. RESULTS: Most LSD analogue users (91%) had also tried LSD. The proportion of U...
May 18, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28517239/the-dose-effect-relationship-of-baclofen-in-alcohol-dependence-a-1-year-cohort-study
#3
Baptiste Pignon, Julien Labreuche, Marine Auffret, Sophie Gautier, Sylvie Deheul, Nicolas Simioni, Olivier Cottencin, Régis Bordet, Alain Duhamel, Benjamin Rolland
OBJECTIVE: Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. METHODS: Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months...
May 18, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28517235/new-psychoactive-substances-purchasing-and-supply-patterns-in-australia
#4
Rachel Sutherland, Raimondo Bruno, Amy Peacock, Paul Dietze, Courtney Breen, Lucinda Burns, Monica J Barratt
OBJECTIVE: To examine the purchasing and supply patterns of new psychoactive substance (NPS) consumers in Australia. METHOD: Data were obtained from a self-selected sample of 296 past-year NPS consumers, with comparisons made across dimethyltryptamine (n = 104), 2C-x (n = 59), NBOMe (n = 27), and synthetic cannabinoid (n = 22) users. RESULTS: Most consumers (58%) nominated a friend as their main NPS source, and almost half (46%) reported that they had supplied NPS to others in the past year (predominantly "social supply")...
May 18, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28517032/novel-psychoactive-substance-consumption-is-more-represented-in-bipolar-disorder-than-in-psychotic-disorders-a-multicenter-observational-study
#5
Tiziano Acciavatti, Matteo Lupi, Rita Santacroce, Andrea Aguglia, Luigi Attademo, Laura Bandini, Paola Ciambrone, Giulia Lisi, Giovanni Migliarese, Federica Pinna, Diego Quattrone, Michele Ribolsi, Maria Salvina Signorelli, Salvatore Calò, Fabrizio Schifano, Massimo di Giannantonio, Giovanni Martinotti
OBJECTIVE: Comorbidities between psychiatric diseases and use of traditional substances of abuse are common. Nevertheless, there are few data regarding the use of novel psychoactive substances (NPS) among psychiatric patients. Aim of this multicentre survey is to investigate the consumption of a number of psychoactive substances in a young psychiatric sample. METHODS: Between December 2013 and September 2015, a questionnaire was administered in 10 Italian psychiatric care facilities to a sample of 671 patients, aged 18-26 (mean age 22...
May 18, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28485125/an-international-survey-on-the-awareness-use-preference-and-health-perception-of-novel-psychoactive-substances-nps
#6
Elena Deligianni, John M Corkery, Fabrizio Schifano, Lisa A Lione
OBJECTIVE: This survey investigated the level of public awareness, preference, and motivation of novel psychoactive substances (NPS) use as well as knowledge of potential associated health risks. METHODS: A Bristol Online Survey was advertised through social media and a drug forum "Bluelight" between January 7 and February 7, 2015. RESULTS: Responses were received from 17 countries, mainly from Europe. Most responses (83%) came from university educated students...
May 8, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28485008/l-carnosine-as-an-adjuvant-to-fluvoxamine-in-treatment-of-obsessive-compulsive-disorder-a-randomized-double-blind-study
#7
Somaye Arabzadeh, Maryam Shahhossenie, Bita Mesgarpour, Farzin Rezaei, Mohammad Reza Shalbafan, Zahra Ghiasi, Shahin Akhondzadeh
BACKGROUND: Dysregulation of glutamate is implicated in the pathogenesis of obsessive-compulsive disorder (OCD). Consistently, glutamate-modulating agents, such as riluzole and memantine have been used in OCD treatment. Previous research has identified some neuroprotective role for L-carnosine potentially via its modulatory effect on glutamate. Here, we assessed the efficacy of L-carnosine as adjuvant to fluvoxamine in OCD treatment. METHODS: Forty-four patients diagnosed with moderate to severe OCD were recruited in a randomized double-blind trial...
May 8, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28421639/cilostazol-adjunctive-therapy-in-treatment-of-negative-symptoms-in-chronic-schizophrenia-randomized-double-blind-placebo-controlled-study
#8
Farzin Rezaei, Bita Mesgarpour, Alireza Jeddian, Atefeh Zeionoddini, Payam Mohammadinejad, Elaheh Salardini, Mona Shahriari, Arefeh Zeinoddini, Shahin Akhondzadeh
OBJECTIVE: To evaluate the efficacy and safety of cilostazol, a selective inhibitor of phosphodiesterase III, as an adjunctive to risperidone in alleviating the negative symptoms of schizophrenia. METHODS: Eighty-four in-patients with diagnosis of chronic schizophrenia participated in a randomized, placebo-controlled trial and underwent 8 weeks of treatment with either cilostazol (50 mg twice a day) or placebo as an adjuvant to risperidone. Participants were assessed using the positive and negative syndrome scale (PANSS) at baseline and at weeks 2, 4, 6, and 8...
April 18, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28370311/diagnostic-clusters-associated-with-an-early-onset-schizophrenia-diagnosis-among-children-and-adolescents
#9
Jeanette M Jerrell, Roger S McIntyre, Chelsea B Deroche
OBJECTIVE: Given the greater severity and chronicity of psychiatric disorders that first declare in individuals under the age of 18, early onset schizophrenia (EOS) and its association with co-occurring psychiatric conditions deserve further investigation. METHODS: Cluster and discriminant analyses were used to examine the heterogeneity of children and adolescents diagnosed with schizophrenia in 1 statewide system of care. A retrospective cohort design was employed, using South Carolina's (USA) Medicaid claims dataset covering outpatient and inpatient medical services between January, 1999 and December, 2013 to identify patients ≤17 years of age...
March 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28370310/pharmacotherapy-effectiveness-for-clinical-subgroups-among-children-and-adolescents-with-early-onset-schizophrenia
#10
Jeanette M Jerrell, Roger S McIntyre, Chelsea B Deroche
OBJECTIVE: This study aims to determine the effectiveness of pharmacotherapies among children and adolescents diagnosed with early onset schizophrenia subgrouped according to their co-occurring psychiatric disorders. METHODS: A retrospective cohort design was employed, using South Carolina's (USA) Medicaid claims dataset covering outpatient and inpatient medical services, between January, 1999 and December, 2013 to identify patients ≤17 years of age. Random effects regression analyses assessed differential changes in acute psychiatric service utilization over time across the 3 subgroups associated with antipsychotic, mood stabilizer, psychostimulant, or antidepressant pharmacotherapy...
March 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28370309/long-term-antipsychotic-use-and-brain-changes-in-schizophrenia-a-systematic-review-and-meta-analysis
#11
REVIEW
Sanna Huhtaniska, Erika Jääskeläinen, Noora Hirvonen, Jukka Remes, Graham K Murray, Juha Veijola, Matti Isohanni, Jouko Miettunen
OBJECTIVE: The association between long-term antipsychotic treatment and changes in brain structure in schizophrenia is unclear. Our aim was to conduct a systematic review and a meta-analysis on long-term antipsychotic effects on brain structures in schizophrenia focusing on studies with at least 2 years of follow-up between MRI scans. DESIGN: Studies were systematically collected using 4 databases, and we also contacted authors for unpublished data. We calculated correlations between antipsychotic dose and/or type and brain volumetric changes and used random effect meta-analysis to study correlations by brain area...
March 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28370308/prescribing-in-schizophrenia-and-psychosis-increasing-polypharmacy-over-time
#12
Adrian Heald, Mark Livingston, Alison Yung, M A De Hert
INTRODUCTION: Diabetes, obesity, and metabolic syndrome are highly prevalent in patients with severe mental illness. Psychotropic polypharmacy is becoming increasingly prevalent within the UK. We determined the change in the number of psychotropic medications prescribed over time and trends in weight and fasting blood glucose. METHODS: One hundred ninety-five individuals with schizophrenia and psychosis on the Severe Mental Illness Register in Cheshire, UK, were followed up between 2004 and 2012...
March 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28370307/open-label-proof-of-concept-study-of-brexanolone-in-the-treatment-of-severe-postpartum-depression
#13
Stephen J Kanes, Helen Colquhoun, James Doherty, Shane Raines, Ethan Hoffmann, David R Rubinow, Samantha Meltzer-Brody
OBJECTIVE: Preclinical evidence indicates that rapid changes in levels of allopregnanolone, the predominant metabolite of progesterone, confer dramatic behavioral changes and may trigger postpartum depression (PPD) in some women. Considering the pathophysiology of PPD (i.e., triggered by reproductive steroids), the need for fast-acting, efficacious treatments and the negative consequences of untreated PPD, there is an increasing focus on developing PPD therapies. Brexanolone (USAN; formerly SAGE-547 Injection), a proprietary injectable allopregnanolone formulation, was evaluated as a treatment for severe PPD in a proof-of-concept, open-label study...
March 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28332719/rs7968606-polymorphism-of-anks1b-is-associated-with-improvement-in-the-panss-general-score-of-schizophrenia-caused-by-amisulpride
#14
Seung-Gul Kang, Ik-Seung Chee, Kwanghun Lee, Jonghun Lee
A recent genome-wide pharmacogenomics study showed that the rs7968606 single-nucleotide polymorphism (SNP) of the ankyrin repeat and sterile alpha motif domain-containing protein 1B (ANKS1B) gene approached the threshold of statistical significance. The aim of this study was to determine the association between the rs7968606 SNP of ANKS1B and the treatment response to amisulpride in schizophrenia patients. In total, 154 participants were enrolled from six university hospitals in Korea. All the subjects were interviewed before and after 6 weeks of amisulpride treatment with the aid of the positive and negative syndrome scale and the clinical global impression-severity scale...
March 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28120489/association-study-between-the-neurexin-1-gene-and-tardive-dyskinesia
#15
Rachel Lanning, Tristram A Lett, Arun K Tiwari, Eva J Brandl, Vincenzo de Luca, Aristotle N Voineskos, Steven G Potkin, Jeffrey A Lieberman, Herbert Y Meltzer, Daniel J Müller, Gary Remington, James L Kennedy, Clement C Zai
OBJECTIVE: Tardive dyskinesia (TD) is a motor side effect that may develop after long-term antipsychotic treatment. Schizophrenia has recently been associated with the Neurexin-1 (NRXN1) gene that codes for a cell adhesion molecule in synaptic communication. METHODS: This study examined five NRXN1 single-nucleotide polymorphisms (SNPs) for possible association with the occurrence and severity of TD in 178 schizophrenia patients of European ancestry. RESULTS: We did not find these SNPs to be significantly associated with TD...
January 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28120488/the-factor-structure-of-the-mystical-experience-questionnaire-meq-reply-to-bouso-et-al-2016
#16
LETTER
Frederick S Barrett, Roland R Griffiths
No abstract text is available yet for this article.
January 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28120487/adjunctive-antidepressant-use-in-schizophrenia-in-china-a-national-survey-2002-2012
#17
Qian Li, Yun-Ai Su, Yu-Tao Xiang, Liang Shu, Xin Yu, Gabor S Ungvari, Chee H Ng, Helen F K Chiu, Yu-Ping Ning, Gao-Hua Wang, Ke-Rang Zhang, Tao Li, Li-Zhong Sun, Jian-Guo Shi, Xian-Sheng Chen, Qi-Yi Mei, Ke-Qing Li, Tian-Mei Si
OBJECTIVE: This study examined the pattern of adjunctive antidepressant use in schizophrenia patients and its demographic and clinical correlates in a nationwide survey in China. METHODS: Fourteen thousand and thirteen patients in 45 Chinese psychiatric hospitals or centers were interviewed (4,486 in 2002, 5,288 in 2006, and 4,239 in 2012). Patients' sociodemographic and clinical characteristics were recorded using a standardized protocol and data collection procedure...
January 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28120486/a-phase-i-randomized-proof-of-clinical-mechanism-study-assessing-the-pharmacokinetics-and-pharmacodynamics-of-the-oral-pde9a-inhibitor-bi-409306-in-healthy-male-volunteers
#18
Katja Boland, Viktoria Moschetti, Chantaratsamon Dansirikul, Solen Pichereau, Lien Gheyle, Frank Runge, Heike Zimdahl-Gelling, Michael Sand
OBJECTIVE: Cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitors are hypothesized to improve cognition in schizophrenia and Alzheimer disease by increasing cGMP levels in certain brain regions. This phase I, randomized, parallel-group, double-blind, placebo-controlled study provides proof-of-mechanism evidence for BI 409306, a novel, oral PDE9A inhibitor. METHODS: In healthy males, exposure of BI 409306 (25-, 50-, 100-, and 200-mg single dose) and placebo was assessed in plasma and cerebrospinal fluid (CSF)...
January 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28120485/effects-of-acute-buspirone-administration-on-inhibitory-control-and-sexual-discounting-in-cocaine-users
#19
Justin C Strickland, B Levi Bolin, Michael R Romanelli, Craig R Rush, William W Stoops
OBJECTIVE: Cocaine users display deficits in inhibitory control and make impulsive choices that may increase risky behavior. Buspirone is an anxiolytic that activates dopaminergic and serotonergic systems and improves impulsive choice (i.e., reduces sexual risk-taking intent) in cocaine users when administered chronically. We evaluated the effects of acutely administered buspirone on inhibitory control and impulsive choice. METHODS: Eleven subjects with a recent history of cocaine use completed this within-subject, placebo-controlled study...
January 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28120484/the-factor-structure-of-the-mystical-experience-questionnaire-meq-reply-to-barrett-griffiths-2016
#20
LETTER
José Carlos Bouso, Eduardo José Pedrero-Pérez, Sam Gandy, Miguel Ángel Alcázar-Córcoles
No abstract text is available yet for this article.
January 2017: Human Psychopharmacology
journal
journal
29468
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"